Cryo-EM snapshots of mycobacterial arabinosyltransferase complex EmbB
EmbB
Mycobacterium tuberculosis
acyl-carrier-protein
arabinoglacatan
arabinosyltransferase
cell wall synthesis
cryo-EM
drug discovery
ethambutol
Journal
Protein & cell
ISSN: 1674-8018
Titre abrégé: Protein Cell
Pays: Germany
ID NLM: 101532368
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
11
2019
accepted:
27
11
2019
pubmed:
5
5
2020
medline:
10
2
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
Inhibition of Mycobacterium tuberculosis (Mtb) cell wall assembly is an established strategy for anti-TB chemotherapy. Arabinosyltransferase EmbB, which catalyzes the transfer of arabinose from the donor decaprenyl-phosphate-arabinose (DPA) to its arabinosyl acceptor is an essential enzyme for Mtb cell wall synthesis. Analysis of drug resistance mutations suggests that EmbB is the main target of the front-line anti-TB drug, ethambutol. Herein, we report the cryo-EM structures of Mycobacterium smegmatis EmbB in its "resting state" and DPA-bound "active state". EmbB is a fifteen-transmembrane-spanning protein, assembled as a dimer. Each protomer has an associated acyl-carrier-protein (AcpM) on their cytoplasmic surface. Conformational changes upon DPA binding indicate an asymmetric movement within the EmbB dimer during catalysis. Functional studies have identified critical residues in substrate recognition and catalysis, and demonstrated that ethambutol inhibits transferase activity of EmbB by competing with DPA. The structures represent the first step directed towards a rational approach for anti-TB drug discovery.
Identifiants
pubmed: 32363534
doi: 10.1007/s13238-020-00726-6
pii: 10.1007/s13238-020-00726-6
pmc: PMC7305291
doi:
Substances chimiques
Bacterial Proteins
0
Ethambutol
8G167061QZ
Pentosyltransferases
EC 2.4.2.-
arabinosyltransferase
EC 2.4.2.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-517Subventions
Organisme : Medical Research Council
ID : MR/S000542/1
Pays : United Kingdom
Références
Science. 2009 May 8;324(5928):801-4
pubmed: 19299584
Nat Struct Mol Biol. 2017 Dec;24(12):1100-1106
pubmed: 29058712
Nature. 2011 Jun 15;474(7351):350-5
pubmed: 21677752
Annu Rev Microbiol. 2015;69:405-23
pubmed: 26488279
Glycobiology. 2005 Feb;15(2):139-51
pubmed: 15371346
Science. 2016 Feb 5;351(6273):608-12
pubmed: 26912703
Curr Opin Struct Biol. 2012 Oct;22(5):540-9
pubmed: 22819665
J Biol Chem. 2005 Feb 18;280(7):5651-63
pubmed: 15546869
J Biol Chem. 2002 May 3;277(18):15874-80
pubmed: 11825906
Antimicrob Agents Chemother. 1997 Oct;41(10):2270-3
pubmed: 9333060
Antimicrob Agents Chemother. 1989 Sep;33(9):1493-9
pubmed: 2817850
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29084750
Mol Microbiol. 2003 Apr;48(1):77-84
pubmed: 12657046
Structure. 2000 Aug 15;8(8):883-95
pubmed: 10997907
J Bacteriol. 2008 Jun;190(12):4335-41
pubmed: 18424526
Glycobiology. 2007 Jun;17(6):35-56R
pubmed: 17261566
PLoS Pathog. 2011 Feb;7(2):e1001299
pubmed: 21383969
Database (Oxford). 2019 Jan 1;2019:
pubmed: 31290951
Science. 2020 Jun 12;368(6496):1211-1219
pubmed: 32327601
J Biol Chem. 2006 Jul 14;281(28):19512-26
pubmed: 16687411
Antimicrob Agents Chemother. 2000 Feb;44(2):326-36
pubmed: 10639358
J Biol Chem. 2001 Dec 28;276(52):48854-62
pubmed: 11677227
J Biol Chem. 1994 Sep 16;269(37):23328-35
pubmed: 8083238
Tuberculosis (Edinb). 2008 Mar;88(2):102-5
pubmed: 18486042
Antimicrob Agents Chemother. 1997 Dec;41(12):2629-33
pubmed: 9420031
Antimicrob Agents Chemother. 2008 Jun;52(6):2027-34
pubmed: 18378710
Glycobiology. 1997 Dec;7(8):1121-8
pubmed: 9455913
Annu Rev Biochem. 2008;77:521-55
pubmed: 18518825
Mol Microbiol. 1990 Nov;4(11):1911-9
pubmed: 2082148
Antimicrob Agents Chemother. 1995 Nov;39(11):2484-9
pubmed: 8585730
Trends Biochem Sci. 2005 Jan;30(1):53-62
pubmed: 15653326
J Biol Chem. 2007 May 18;282(20):14729-40
pubmed: 17387176
Yonsei Med J. 2002 Feb;43(1):59-64
pubmed: 11854934